MA52792A - Formes cristallines et monohydrate de 6- [(3s,4s)-4-méthyl-1-(pyrimidin-2-ylméthyl) pyrrolidin-3-yl]-3-tétrahydropyran-4-yl-7h-imidazo [1,5-a] pyrazin-8-one - Google Patents

Formes cristallines et monohydrate de 6- [(3s,4s)-4-méthyl-1-(pyrimidin-2-ylméthyl) pyrrolidin-3-yl]-3-tétrahydropyran-4-yl-7h-imidazo [1,5-a] pyrazin-8-one

Info

Publication number
MA52792A
MA52792A MA052792A MA52792A MA52792A MA 52792 A MA52792 A MA 52792A MA 052792 A MA052792 A MA 052792A MA 52792 A MA52792 A MA 52792A MA 52792 A MA52792 A MA 52792A
Authority
MA
Morocco
Prior art keywords
pyrazin
tetrahydropyran
imidazo
pyrrolidin
pyrimidin
Prior art date
Application number
MA052792A
Other languages
English (en)
Inventor
Suzanne Buttar
Kuangchu Dai
Adam Ross Patterson
Mateusz Pitak
Ioana Sovago
Samuel Alexander Stratford
Haojuan Wei
Jun Xu
Peng Zhou
Original Assignee
Imara Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imara Inc filed Critical Imara Inc
Publication of MA52792A publication Critical patent/MA52792A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MA052792A 2018-05-25 2019-05-23 Formes cristallines et monohydrate de 6- [(3s,4s)-4-méthyl-1-(pyrimidin-2-ylméthyl) pyrrolidin-3-yl]-3-tétrahydropyran-4-yl-7h-imidazo [1,5-a] pyrazin-8-one MA52792A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862676381P 2018-05-25 2018-05-25
US201962788323P 2019-01-04 2019-01-04

Publications (1)

Publication Number Publication Date
MA52792A true MA52792A (fr) 2021-04-14

Family

ID=68617192

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052792A MA52792A (fr) 2018-05-25 2019-05-23 Formes cristallines et monohydrate de 6- [(3s,4s)-4-méthyl-1-(pyrimidin-2-ylméthyl) pyrrolidin-3-yl]-3-tétrahydropyran-4-yl-7h-imidazo [1,5-a] pyrazin-8-one

Country Status (18)

Country Link
US (1) US12006319B2 (fr)
EP (2) EP4349403A3 (fr)
JP (1) JP2021526134A (fr)
KR (1) KR20210014662A (fr)
CN (2) CN117843645A (fr)
AU (1) AU2019275075A1 (fr)
BR (2) BR122023022641A2 (fr)
CA (1) CA3100988A1 (fr)
DK (1) DK3801526T3 (fr)
FI (1) FI3801526T3 (fr)
HR (1) HRP20240363T1 (fr)
IL (1) IL278875A (fr)
LT (1) LT3801526T (fr)
MA (1) MA52792A (fr)
MX (2) MX2020012636A (fr)
PT (1) PT3801526T (fr)
SI (1) SI3801526T1 (fr)
WO (1) WO2019226944A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2971969T3 (es) 2015-07-07 2024-06-10 H Lundbeck As Inhibidores de PDE9 con cadena principal de imidazopirazinona para el tratamiento de enfermedades periféricas
CN117843645A (zh) 2018-05-25 2024-04-09 伊马拉公司 一种pde9抑制剂的一水合物和结晶形态
EP3965768A1 (fr) * 2019-05-07 2022-03-16 Imara Inc. Inhibiteurs de pde9 pour le traitement de la thalassémie

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB587992A (en) 1944-12-11 1947-05-12 Charles William Scaife Improvements in and relating to the production of organic nitrogen compounds
US3578687A (en) 1968-01-30 1971-05-11 Texaco Inc Process for producing 4-nitroalkanoic acids
US3819561A (en) 1970-10-23 1974-06-25 Aerojet General Co Wetting agents for non-aqueous dispersions
JPS5313608B2 (fr) 1972-06-16 1978-05-11
JPS5318013B2 (fr) 1973-03-19 1978-06-13
US4599430A (en) 1981-12-21 1986-07-08 The Standard Oil Company Nitrogenation of hydrocarbons, including the production of maleimide
JPS62132804A (ja) 1985-12-05 1987-06-16 Aguro Kanesho Kk 植物生長調節剤
US5412137A (en) 1993-06-07 1995-05-02 Sandoz Ltd. Process for preparing phosphinyloxy propanaminium inner salt derivatives
CN1138541C (zh) 1994-08-08 2004-02-18 德彪药品股份有限公司 一种药学上稳定的奥沙利铂制剂
CA2202503C (fr) 1994-10-13 2008-07-15 Antonio Ferrante Acides gras polyinsatures modifies
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5741211A (en) 1995-10-26 1998-04-21 Medtronic, Inc. System and method for continuous monitoring of diabetes-related blood constituents
GB9618420D0 (en) 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
WO1999022719A1 (fr) 1997-10-30 1999-05-14 Morishita Jintan Co., Ltd. Preparation de capsule contenant un acide gras insature ou un derive de celui-ci, et procede de fabrication
ID25871A (id) 1997-11-12 2000-11-09 Bayer Ag Imidazotriazinon tersubstitusi-2-fenil
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
AU5565599A (en) 1998-08-14 2000-03-06 Dante J. Marciani Chemically modified saponins and the use thereof as adjuvants
SK10322001A3 (sk) 1999-01-20 2002-07-02 Arzneimittelwerk Dresden Gmbh Spôsob prípravy imidazo [1,5-a]pyrido[3,2-e]pyrazínov, farmaceutické prostriedky obsahujúce takéto zlúčeniny a spôsob výroby farmaceutického prostriedku
IL145712A0 (en) 1999-04-01 2002-07-25 Esperion Therapeutics Inc Ether compounds, compositions, and uses thereof
WO2001006983A2 (fr) 1999-07-22 2001-02-01 Incell Corporation, Llc Acides gras servant a reduire au minimum les effets secondaires d'une therapie anticancereuse
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
AUPQ291499A0 (en) 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
US6346231B1 (en) 1999-10-06 2002-02-12 Joar Opheim Flavored gelatin capsule and method of manufacture
IL139455A0 (en) 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US20010037598A1 (en) 1999-12-14 2001-11-08 Suppes Galen J. Process for producing cetane improvers from triglycerides
WO2001060778A2 (fr) 2000-02-16 2001-08-23 The Brigham And Women's Hospital, Inc. Mediateurs lipidiques actives par l'aspirine
AR032318A1 (es) 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
AR030416A1 (es) 2000-04-13 2003-08-20 Pharmacia Corp COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
AR034120A1 (es) 2000-04-13 2004-02-04 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
CA2412232C (fr) 2000-06-28 2010-03-30 Zambon Group S.P.A. Procede de preparation de nitroalcenes
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
ATE365037T1 (de) 2001-03-02 2007-07-15 Debiopharm Sa Verwendung eines eine oxaliplatinlösung beinhaltenden fläschchens
DE60223670T2 (de) 2001-04-18 2008-03-06 Prometic Biosciences Inc., Mont-Royal Fettsäuren als Faktoren für das Überleben und die Aktivierung von Neutrophilen.
US7105556B2 (en) 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
WO2002102364A1 (fr) 2001-06-18 2002-12-27 Yamada, Sachiko Preparations medicamenteuses agonistes ppar$g(g)
CN1571672A (zh) 2001-08-17 2005-01-26 匹兹堡大学 给予雌二醇代谢物治疗或预防肥胖症、代谢综合征、糖尿病以及血管和肾脏疾病
GB0123961D0 (en) 2001-10-05 2001-11-28 Astrazeneca Ab Process and intermediates
PL370599A1 (en) 2001-11-02 2005-05-30 Pfizer Products Inc. Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
US20030166716A1 (en) 2001-11-06 2003-09-04 Serhan Charles N. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
GB2388111A (en) 2002-05-01 2003-11-05 Bayer Ag Novel imidazotriazinone compounds
US6684626B1 (en) 2002-07-30 2004-02-03 General Electric Company Aircraft gas turbine engine with control vanes for counter rotating low pressure turbines
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
CA2875522A1 (fr) 2002-08-20 2004-03-04 Philera New Zealand Limited Formes posologiques et traitements s'y rapportant
AU2003272738B2 (en) 2002-09-27 2010-04-01 Martek Biosciences Corporation Docosahexaenoic acid for improved glycemic control
WO2004037311A2 (fr) 2002-10-21 2004-05-06 Kensey Nash Corporation Dispositif et methodes d'administration sequentielle, locale de plusieurs agents cytotoxiques et assemblage guide de tissus de reparation de blessures
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2005016864A1 (fr) 2003-07-29 2005-02-24 The Arizona Disease Control Research Commission Agents anticancereux a base de nitro-alcene conjugue utilisant le metabolisme des isoprenoides
US20050136103A1 (en) 2003-09-17 2005-06-23 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
CA2543522A1 (fr) 2003-10-31 2005-05-12 Pfizer Products Inc. Inhibition de la phosphodiesterase 9 comme traitement d'etats associes a l'obesite
WO2005073164A1 (fr) 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Molecules porteuses et therapeutiques
CA2563533C (fr) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capables de faciliter la penetration a travers une barriere biologique
US7776916B2 (en) 2004-04-28 2010-08-17 The Uab Research Foundation Nitrated lipids and methods of making and using thereof
NZ553263A (en) 2004-07-19 2010-06-25 Biocon Ltd Insulin-oligomer conjugates, formulations and uses thereof
MY139689A (en) 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
EP1772149A1 (fr) 2004-07-27 2007-04-11 Kowa Company. Ltd. Médicament pour la prévention ou le traitement du diabète
EP1824809A4 (fr) 2004-11-19 2010-03-03 Martek Biosciences Corp Oxylipines provenant d'acides gras polyinsatures a longue chaine et procedes permettant de les fabriquer et de les utiliser
WO2006058250A2 (fr) 2004-11-24 2006-06-01 Spi Pharma, Inc. Compositions a desintegration orale
AU2011202664B2 (en) 2004-12-08 2012-04-05 Cedars-Sinai Medical Center Methods for diagnosis and treatment of Crohn's disease
US20070032420A1 (en) 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
EP1928237A4 (fr) 2005-09-02 2011-03-09 Abbott Lab Nouveaux heterocycles a base imidazo
GB0522569D0 (en) 2005-11-04 2005-12-14 Univ Bath Biocompatible drug delivery device
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US20090264483A1 (en) 2006-07-14 2009-10-22 Cedars-Sinai Medical Center METHODS OF USING PPAR-gamma AGONISTS AND CASPASE-DEPENDENT CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
CN101528218A (zh) 2006-07-19 2009-09-09 雷索维克斯药品公司 治疗粘膜炎的组合物和方法
WO2008029589A1 (fr) 2006-09-08 2008-03-13 Tokuyama Corporation Procédé et matériel servant à produire un nitrure d'un élément du groupe iii
CA2672591A1 (fr) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. Agent therapeutique de l'uropathie
KR101555384B1 (ko) 2006-12-13 2015-09-23 아스카 세이야쿠 가부시키가이샤 퀴녹살린 유도체
EP2120920A4 (fr) 2007-02-20 2011-06-15 Martek Biosciences Corp Oxylipines derivées d'acides gras polyinsaturés à chaîne longue et leurs procédé de production et d'utilisation
SI2152712T1 (sl) 2007-05-11 2012-03-30 Pfizer Amino heterociklične spojine
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
DK2180787T3 (da) 2007-08-01 2014-02-03 Univ Pittsburgh Nitrooliesyremodulering af type ii-diabetes
AU2008301895A1 (en) 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Oxylipin compounds for treating autoimmune diseases
ES2638463T3 (es) * 2008-03-10 2017-10-20 Takeda Pharmaceutical Company Limited Cristal de compuesto de bencimidazol
EP2271929B1 (fr) 2008-04-18 2015-11-25 The University of Utah Research Foundation Utilisation de lipides nitrés pour le traitement de troubles lipidiques et de l'obésité, et d'affections lipidiques et liées à l'obésité
WO2009134383A2 (fr) 2008-05-01 2009-11-05 Complexa Inc. Acides gras à substitution vinyle
WO2009149496A1 (fr) 2008-06-10 2009-12-17 Central Northern Adelaide Health Service Traitement du diabète, de ses complications et de troubles associés
WO2009155439A2 (fr) 2008-06-19 2009-12-23 University Of Utah Research Foundation Utilisation de lipides nitrés pour le traitement d'effets secondaires de thérapies médicales toxiques
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2010012777A1 (fr) 2008-07-29 2010-02-04 Nerviano Medical Sciences S.R.L. Combinaison thérapeutique contenant un inhibiteur de cdk et un agent antinéoplasique
US9139554B2 (en) 2008-10-09 2015-09-22 Tekmira Pharmaceuticals Corporation Amino lipids and methods for the delivery of nucleic acids
US8937194B2 (en) 2008-12-31 2015-01-20 Nitromega Corp. Topical compositions containing nitro fatty acids
AU2009334476B2 (en) 2008-12-31 2013-08-29 Nitromega Corp. Nutraceuticals containing nitro fatty acids
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
US20100286271A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Nitro-alkyl Compound Compositions
US20100286272A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications
US20100286257A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging
US20110082147A1 (en) 2009-07-24 2011-04-07 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
JP2013500275A (ja) 2009-07-29 2013-01-07 フェノメノーム ディスカバリーズ インク ヒドロキシ脂肪酸化合物並びに疾患治療及び診断のためのその使用
EP2459189A4 (fr) 2009-07-31 2013-01-16 Univ Pittsburgh Acides gras comme agents anti-inflammatoires
US9260432B2 (en) 2009-09-02 2016-02-16 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
WO2011030351A2 (fr) 2009-09-03 2011-03-17 Rubicon Research Private Limited Compositions pharmaceutiques au goût masqué
EP2483233A4 (fr) 2009-10-02 2013-08-14 Complexa Inc Hétéroatome contenant des acides gras substitués
CN102822152A (zh) 2009-11-09 2012-12-12 诺瓦德克斯制药股份有限公司 新颖的1,3-噁唑烷化合物及其作为肾素抑制剂的用途
WO2011098746A1 (fr) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Sels d'addition acide cristallins de l'énantiomère (5r) de la pioglitazone
WO2011113507A2 (fr) 2010-03-15 2011-09-22 Ulrich Dietz Utilisation d'acides nitrocarboxyliques pour le traitement, le diagnostic et la prophylaxie de motifs de cicatrisation agressifs
JP2013526865A (ja) 2010-05-13 2013-06-27 ニトロメガ コーポレーション ニトロ脂肪酸、神経保護および／または認識減退の抑制
JP2013534930A (ja) 2010-06-28 2013-09-09 コンプレクサ，インコーポレイテッド 糖尿病を治療するための多成分調剤
EP3181566A1 (fr) 2010-09-20 2017-06-21 Ironwood Pharmaceuticals, Inc. Composes imidazotriazinones
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP2744491B1 (fr) 2011-08-19 2020-07-29 The University of Utah Research Foundation Polythérapie avec des lipides nitrés et des inhibiteurs du système rénine-angiotensine-aldostérone
CN103930423B (zh) 2011-10-07 2015-09-16 卫材Rd管理有限公司 吡唑并喹啉衍生物
CN106905324B (zh) 2011-10-10 2018-09-25 H.隆德贝克有限公司 具有咪唑并吡嗪酮骨架的pde9抑制剂
US9271952B2 (en) 2011-10-11 2016-03-01 Complexa, Inc. Compositions and methods for treating nephropathy
DE102012008730A1 (de) 2011-12-02 2013-06-06 Dr. Budz GmbH Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung
CN104093720B (zh) 2012-01-26 2017-04-12 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
CN104136423B (zh) 2012-02-01 2019-03-08 希望之城 核糖核苷酸还原酶抑制剂和使用方法
CA2863765A1 (fr) 2012-02-03 2013-08-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Acides gras comme agents anti-inflammatoires
US10435367B2 (en) 2013-03-14 2019-10-08 City Of Hope Indirubin derivatives, and uses thereof
WO2013142269A1 (fr) 2012-03-19 2013-09-26 Envivo Pharmaceuticals, Inc. Composés d'imidazotriazinone
US10058688B2 (en) 2012-05-09 2018-08-28 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
WO2014036555A1 (fr) 2012-08-31 2014-03-06 Taris Biomedical, Inc. Systèmes d'administration de médicaments et méthodes de traitement du cancer de la vessie incluant de l'oxaliplatine
US20140271844A1 (en) 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids
EP2983730B1 (fr) 2013-04-10 2019-10-16 Massachusetts Institute of Technology Dispositifs et procédés d'administration de médicament locale pour traiter un cancer
CN105339006A (zh) 2013-05-10 2016-02-17 尼特罗米加公司 含有脂肪酸和亚硝酸盐的营养或膳食补充剂
US20150051283A1 (en) 2013-06-14 2015-02-19 Complexa, Inc. Composition and method for inhibition of pkng from mycobacterium tuberculosis
EP3033138A4 (fr) 2013-08-12 2017-03-29 Nanomedical Systems Inc. Dispositif et procédé pour la libération prolongée d'agent thérapeutique à faible solubilité dans l'eau dans un solubilisant
WO2015073527A1 (fr) 2013-11-12 2015-05-21 Complexa, Inc. Nitroalcène-tocophérols et analogues de ceux-ci utilisables dans le cadre du traitement et de la prévention d'affections associées à l'inflammation
WO2015185499A1 (fr) 2014-06-06 2015-12-10 H. Lundbeck A/S Inhibiteurs pde9 présentant un squelette 1-benzyl-2,5,6,8-tétrahydro-3-oxo-2,7-naphtyridine-4-carbonitrile
WO2016161285A1 (fr) 2015-04-02 2016-10-06 Aobiome Llc Production d'acides gras nitrés et d'hydrocarbures nitrés au moyen de bactéries oxydant l'ammoniac
ES2971969T3 (es) * 2015-07-07 2024-06-10 H Lundbeck As Inhibidores de PDE9 con cadena principal de imidazopirazinona para el tratamiento de enfermedades periféricas
KR20180098222A (ko) 2015-10-02 2018-09-03 컴플렉사, 인코포레이티드 활성화된 지방산의 치료학적 유효량을 이용한 질환의 예방, 치료 및 역행
US9771366B2 (en) 2016-02-19 2017-09-26 Phoenix Molecular Design Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors
BR112019000005A2 (pt) 2016-07-06 2019-04-16 H. Lundbeck A/S inibidores de pde9 para o tratamento de doenças periféricas
US11370795B2 (en) 2017-05-26 2022-06-28 Imara Inc. Process for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
CN117843645A (zh) 2018-05-25 2024-04-09 伊马拉公司 一种pde9抑制剂的一水合物和结晶形态
AU2019328299A1 (en) 2018-08-31 2021-04-22 Cardurion Pharmaceuticals, Inc. PDE9 inhibitors for treating sickle cell disease
JP2022527630A (ja) 2019-04-05 2022-06-02 イマラ インク． 鎌状赤血球症を治療するためのｐｄｅ９阻害剤
EP3965768A1 (fr) 2019-05-07 2022-03-16 Imara Inc. Inhibiteurs de pde9 pour le traitement de la thalassémie

Also Published As

Publication number Publication date
WO2019226944A1 (fr) 2019-11-28
EP4349403A2 (fr) 2024-04-10
SI3801526T1 (sl) 2024-05-31
CN117843645A (zh) 2024-04-09
HRP20240363T1 (hr) 2024-06-07
LT3801526T (lt) 2024-04-10
MX2020012636A (es) 2021-01-29
CN112469413B (zh) 2024-01-12
DK3801526T3 (da) 2024-03-25
US20210107911A1 (en) 2021-04-15
JP2021526134A (ja) 2021-09-30
CA3100988A1 (fr) 2019-11-28
MX2023009562A (es) 2023-08-22
US12006319B2 (en) 2024-06-11
EP3801526B1 (fr) 2023-12-27
IL278875A (en) 2021-01-31
BR112020024019A2 (pt) 2021-02-23
BR122023022641A2 (pt) 2024-02-20
AU2019275075A1 (en) 2021-01-14
FI3801526T3 (fi) 2024-03-20
EP3801526A1 (fr) 2021-04-14
CN112469413A (zh) 2021-03-09
EP3801526A4 (fr) 2022-04-06
KR20210014662A (ko) 2021-02-09
EP4349403A3 (fr) 2024-06-05
PT3801526T (pt) 2024-03-26

Similar Documents

Publication Publication Date Title
MA52792A (fr) Formes cristallines et monohydrate de 6- [(3s,4s)-4-méthyl-1-(pyrimidin-2-ylméthyl) pyrrolidin-3-yl]-3-tétrahydropyran-4-yl-7h-imidazo [1,5-a] pyrazin-8-one
IL257622B (en) Methods and preparations for the treatment of persistent infections
MA46054A (fr) Procédé de préparation de pyrazolo[1,5-a]pyrimidines et de sels de celles-ci
MA48779A (fr) Formes cristallines d'inhibiteur de fgfr et leurs procédés de préparation
ES2401192T8 (es) Deazapurinas útiles como inhibidores de janus cinasas
EG25081A (en) Use of prolines for improving growth and/or yield.
ECSP088345A (es) Nuevas pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina
CR9878A (es) Tratamiento y profilaxis de microangiopatias
DK1765288T3 (da) Tobramycinpræparater til behandling af endobronchiale infektioner
WO2015195862A8 (fr) Formes cristallines de l'acétamide 2-((4s)-6- (4-chlorophényl)-1-méthyl-4 h-benzo [c] isoxazolo [4s5-e] azépin-4-yle)
BR0309573A (pt) Acúmulo celular de análogos de fosfonato de compostos inibidores de hiv protease
MX2016008453A (es) Formas cristalinas de analogos de sofosbuvir antiviral.
NL2000375A1 (nl) Pyrimidinederivaten voor de behandeling van abnormale celgroei.
EA201890547A1 (ru) Способ получения ингибитора parp, кристаллические формы и их применения
WO2010015815A3 (fr) Composés pour le traitement d'infections flavivirales
WO2015195863A8 (fr) 2-((4s)-6-(4-chlorophényl)-1-méthyl-4h-benzo[c]isoxazolo[4,5-e]azépine-4-yl)acétamide hydraté
MX2021002042A (es) Inhibidores de arginasa y sus metodos de uso.
DK3436019T3 (da) (1s,4s)-4-(2-(((3s,4r)-3-fluortetrahydro-2h-pyran-4-yl)amino)-8-((2,4,6-trichlorphenyl)amino)-9h-purin-9-yl)-1-methylcyclohexan-1-carboxamid og fremgangsmåder til anvendelse deraf
EP3730492A4 (fr) Composé pyrazolo[1,5-a]pyrimidine substitué, composition pharmaceutique et utilisation associée
DE602006009779D1 (de) Verfahren zur prophylaxe und/oder therapie von infektionen der vagina und vulva
AU2003209308A1 (en) Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection
WO2018170236A9 (fr) Inhibiteurs de cdpk1, compositions et procédés associés
EA202092762A1 (ru) МОНОГИДРАТНАЯ И КРИСТАЛЛИЧЕСКАЯ ФОРМЫ 6-[(3S,4S)-4-МЕТИЛ-1-(ПИРИМИДИН-2-ИЛМЕТИЛ)ПИРРОЛИДИН-3-ИЛ]-3-ТЕТРАГИДРОПИРАН-4-ИЛ-7H-ИМИДАЗО[1,5-a]ПИРАЗИН-8-ОНА
CL2012000349A1 (es) Formas cristalinas hermi hidrato ha, a, b, c y d de (s)-n-((s)-1-cicloexil-2-{(s)-2-[4-(4-fluoro-benzoil)-tiazol-2-il]-pirrolidin-1-il}-2-oxo-etil)-2-metil-amino-propionamida; y su uso como inhibidor de una proteina apototica.
EP3938287A4 (fr) Bouchons de flacons pour traitement ou analyse biologique